COVID Treatment

Hearing and vision may not be considered hierarchically superior senses anymore, as a new study sheds light on the importance of taste and smell for quality of life.

SARS-CoV-2 infection was associated with post-COVID-19 conditions for children, with associated risk factors including length of hospitalization, number of acute symptoms, and older age.

Results of analysis also show they have a much higher incidence of dying in the hospital than those without the virus.

People who regularly fasted for decades had lower risk of hospitalization or death from COVID-19, adding to the potential health benefits of intermittent fasting.

Paxlovid treats COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

As we learn more about inflammatory syndromes, we may get better at using laboratory tests to identify and isolate the actual cellular and chemical processes that drive them.

Pharmacy and public health have a long history of collaboration during an emergency.

Analysis shows that individuals who received treatment within 3 days of symptom onset with tixagevimab and cilgavimab reduced their risk by 88% compared with the placebo.

Study results showed that a lower proportion of participants treated with LAGEVRIO had an acute care visit compared with those who received the placebo.

Paxlovid treats COVID-19 in adults who do not require supplemental oxygen and who are at an increased risk of progression to severe disease.